Predictions
Sernova Corp.
Start price
Target price
Perf. (%)
€0.53
30.12.22
30.12.22
€5.00
30.12.25
30.12.25
-10.84%
15.12.23
15.12.23
Could be very worthwhile Investment >20% year
HTG Molecular Diagnostics Inc.
Start price
Target price
Perf. (%)
€3.79
27.12.22
27.12.22
-
27.12.23
27.12.23
-90.75%
29.07.23
29.07.23
Capable Management
Risky Investment
No uniques
No Innovation
HTG Molecular Diagnostics Inc.
Start price
Target price
Perf. (%)
€19.20
12.12.22
12.12.22
€0.000
12.12.23
12.12.23
-63.50%
15.12.22
15.12.22
Capable Management
Risky Investment
No uniques
No Innovation
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€1.24
17.11.22
17.11.22
-
17.11.23
17.11.23
0.48%
26.12.22
26.12.22
Risky Investment
Crossject S.A.
Start price
Target price
Perf. (%)
€4.04
12.11.22
12.11.22
€4.50
12.11.23
12.11.23
5.82%
13.11.23
13.11.23
Could be worthwhile Investment >10% per year
Euromedis Groupe
Start price
Target price
Perf. (%)
€4.10
04.10.22
04.10.22
-
04.10.23
04.10.23
14.15%
25.10.22
25.10.22
Probably not worthwhile Investment
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€1.65
18.09.22
18.09.22
-
18.09.23
18.09.23
-3.77%
01.10.22
01.10.22
Risky Investment
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€1.62
14.09.22
14.09.22
-
14.09.23
14.09.23
1.70%
17.09.22
17.09.22
Risky Investment
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€2.62
13.09.22
13.09.22
-
13.09.23
13.09.23
-37.10%
17.09.22
17.09.22
Could be very worthwhile Investment >20% year
Crossject S.A.
Start price
Target price
Perf. (%)
€4.71
16.08.22
16.08.22
€5.00
16.08.23
16.08.23
-14.13%
12.11.22
12.11.22
Could be worthwhile Investment >10% per year
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€2.91
13.08.22
13.08.22
€1.00
13.08.23
13.08.23
-12.70%
23.08.22
23.08.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Bio-Gate AG
Start price
Target price
Perf. (%)
€3.72
07.08.22
07.08.22
-
07.08.23
07.08.23
-13.98%
26.08.22
26.08.22
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€2.24
24.06.22
24.06.22
€5.00
24.06.23
24.06.23
-1.57%
26.06.22
26.06.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€1.77
10.06.22
10.06.22
€0.20
10.06.23
10.06.23
24.58%
26.06.22
26.06.22
Valuable balance sheet
Probably not worthwhile Investment
very negative Cash Flow expected
Junk rating
Newegg Commerce Inc.
Start price
Target price
Perf. (%)
€5.95
02.05.22
02.05.22
€12.00
02.05.23
02.05.23
-25.71%
16.05.22
16.05.22
Could be very worthwhile Investment >20% year
Newegg Commerce Inc.
Start price
Target price
Perf. (%)
€5.95
19.04.22
19.04.22
€11.00
19.04.23
19.04.23
0.00%
02.05.22
02.05.22
Could be very worthwhile Investment >20% year
Bio-Gate AG
Start price
Target price
Perf. (%)
€3.16
09.04.22
09.04.22
-
09.04.23
09.04.23
0.00%
18.04.22
18.04.22
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Newegg Commerce Inc.
Start price
Target price
Perf. (%)
€6.95
07.04.22
07.04.22
-
07.04.23
07.04.23
-17.99%
14.04.22
14.04.22
Probably not worthwhile Investment
Newegg Commerce Inc.
Start price
Target price
Perf. (%)
€6.20
05.04.22
05.04.22
€11.50
05.04.23
05.04.23
-4.03%
19.04.22
19.04.22
Could be very worthwhile Investment >20% year
InVivo Therapeutics Holdings
Start price
Target price
Perf. (%)
€7.59
01.04.22
01.04.22
€12.50
01.04.23
01.04.23
-76.56%
04.03.23
04.03.23
Could be worthwhile Investment >10% per year
Vyant Bio Inc.
Start price
Target price
Perf. (%)
€8.50
30.03.22
30.03.22
-
30.03.23
30.03.23
-24.12%
31.03.22
31.03.22
Risky Investment
PAVmed Inc
Start price
Target price
Perf. (%)
€1.35
21.03.22
21.03.22
€8.00
21.03.23
21.03.23
-14.92%
02.04.22
02.04.22
Could be worthwhile Investment >10% per year
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Revenue decline/stagnation expected
PAVmed Inc
Start price
Target price
Perf. (%)
€1.41
20.03.22
20.03.22
-
20.03.23
20.03.23
-80.13%
21.03.23
21.03.23
Probably not worthwhile Investment